SOCIETY OF CHEMICAL MANUFACTURERS & AFFILIATES

Issues related to implementation and potential reform of the Toxic Substances Control Act (TSCA), including EPA's New Chemicals Program and review of new chemical submissions. Issues related to EPA implementation of TSCA Section 8(a)(7) PFAS reporting requirements, including reporting burden, exemptions, historical data requirements, and implementation timelines. Issues related to EPA chemical risk evaluations and risk management regulations under TSCA, including workplace protections, conditions of use, compliance requirements, and impacts on specialty chemical manufacturers. Issues related to federal policies affecting domestic specialty chemical manufacturing capacity and availability of critical chemical inputs.

Issues related to reshoring and expansion of domestic specialty chemical manufacturing capacity. Issues related to federal policies supporting domestic production of pharmaceutical ingredients, key starting materials, and other critical chemical inputs. Issues related to regulatory policies affecting investment in and competitiveness of U.S. chemical manufacturing.

Issues related to tariffs, international trade, and the competitiveness of U.S. specialty chemical manufacturing. Issues related to chemical supply chain resilience, import dependence, domestic production capacity, and availability of critical chemical inputs. Issues related to U.S. International Trade Commission examination of U.S. chemical manufacturing competitiveness and supply chains.

Issues related to the Federal Aviation Administration's proposed rule governing unmanned aircraft systems (UAS) operations over certain fixed-site facilities, including chemical manufacturing facilities; facility eligibility criteria; protection of confidential facility information; implementation timelines; and coordination with the Department of Homeland Security and Cybersecurity and Infrastructure Security Agency.

Issues related to pharmaceutical supply chain resilience and expansion of domestic manufacturing capacity for active pharmaceutical ingredients, key starting materials, and critical chemical inputs. Issues related to federal policies intended to reduce U.S. reliance on foreign sources for essential medicines and pharmaceutical inputs, including the ASPR 86 essential medicines initiative. Issues related to regulatory and federal policy barriers affecting investment in domestic pharmaceutical and specialty chemical manufacturing.

Issues related to Occupational Safety and Health Administration respiratory protection requirements and proposed revisions to medical evaluation requirements for employees using filtering facepiece respirators and powered air-purifying respirators.